and potentially direct agonists of non-prostanoid IP (prostacyclin) receptors and soluble guanylate cyclase. As pulmonary remodeling in PAH shares common features of the cancer physiopathology ...
Currently, four classes of pulmonary vasodilators have been approved: (1) calcium-channel antagonists, (2) prostacyclin analogues, (3) endothelin receptor antagonists, and (4) phosphodiesterase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback